A Randomized, Parallel, Double-Blind, Placebo-Controlled, Dose Regimen Finding Study to Evaluate the Safety and Efficacy of TRU-015 in Subjects With Active Seropositive Rheumatoid Arthritis on a Background of Methotrexate.
Phase of Trial: Phase II
Latest Information Update: 26 Aug 2014
At a glance
- Drugs TRU 015 (Primary)
- Indications Rheumatoid arthritis
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Sponsors Pfizer
- 31 Aug 2018 Biomarkers information updated
- 15 Jun 2013 Results for part A presented at the 14th Annual Congress of the European League Against Rheumatism.
- 14 Jun 2010 Primary endpoint 'American College of Rheumatology 50% response criteria' has not been met.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History